Cellectar shares surge 10.44% intraday after reporting EMA CMA submission progress for iopofosine I-131 and initiating Phase 1b trial for CLR 125 in triple-negative breast cancer.

Cellectar Biosciences surged 10.44% intraday following the announcement of key clinical and regulatory advancements. The company initiated a Phase 1b dose-finding study for CLR 125 in triple-negative breast cancer (TNBC), a critical step in its pipeline, and reiterated plans to submit a Conditional Marketing Authorization (CMA) for iopofosine I-131 to the European Medicines Agency (EMA) by Q3 2026, targeting potential 2027 EU commercialization for Waldenström Macroglobulinemia. Additionally, the 2025 financial results highlighted a 51.1% reduction in net loss year-over-year, improved cash runway into Q3 2026, and disciplined cost management. These developments signaled regulatory momentum, clinical progress, and improved financial stability, collectively driving investor optimism. The stock’s sharp intraday gain aligns with the positive implications of these milestones, reflecting market confidence in Cellectar’s therapeutic pipeline and strategic execution.